Neurokinin 3 receptor antagonism for menopausal hot flashes.

Abstract

Menopausal hot flashes are common and debilitating. Menopausal Hormone Therapy (MHT) is effective for hot flashes but has risks and side effects that limit its use. NK3 receptor antagonism has emerged as a novel therapeutic strategy, leading to the recent FDA approval of fezolinetant, a first-in-class nonhormonal treatment for menopausal hot flashes. To view this Bench to Bedside, open or download the PDF.

• Authors: Alexander N Comninos, Waljit S Dhillo
• Journal: Cell (Cell) Vol. 186 Issue 16 Pg. 3332-3332.e1 (08 03 2023) ISSN: 1097-4172 [Electronic] United States
• PMID: 37541194 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2023 Elsevier Inc. All rights reserved.

Chemical References

• Receptors, Neurokinin-3
• fezolinetant
• Thiadiazoles

Topics

• Humans
• Hot Flashes (drug therapy)
• Menopause
• Receptors, Neurokinin-3 (antagonists & inhibitors)
• Thiadiazoles (therapeutic use)